Spero Therapeutics Inc
SPRO2.420USD
0.0000.00%
收盘 02/06, 16:00（美东）报价延迟15分钟
136.27M总市值
亏损市盈率 TTM
关于 Spero Therapeutics Inc 公司
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc简介
公司代码SPRO
公司名称Spero Therapeutics Inc
上市日期Nov 02, 2017
CEORajavelu (Esther)
员工数量32
证券类型Ordinary Share
年结日Nov 02
公司地址675 Massachusetts Ave Ste 14
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02139-3309
电话18572421600
网址https://sperotherapeutics.com/
公司代码SPRO
上市日期Nov 02, 2017
CEORajavelu (Esther)
Spero Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
418.97K
+230558.00%
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
166.72K
+21414.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+20000.00%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
418.97K
+230558.00%
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
166.72K
+21414.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
业务USD
名称
营收
占比
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
地区USD
名称
营收
占比
United States
5.44M
100.00%
业务
地区
业务USD
名称
营收
占比
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
股东统计
更新时间: 2月7日 周六
更新时间: 2月7日 周六
持股股东
股东类型
持股股东
持股股东
占比
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
其他
70.37%
持股股东
持股股东
占比
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
其他
70.37%
股东类型
持股股东
占比
Corporation
20.51%
Hedge Fund
6.27%
Investment Advisor
5.88%
Individual Investor
2.87%
Investment Advisor/Hedge Fund
2.52%
Venture Capital
1.64%
Research Firm
0.20%
Bank and Trust
0.02%
其他
60.09%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
108
9.31M
16.53%
-3.08M
2025Q3
106
9.05M
16.08%
-5.89M
2025Q2
114
26.06M
46.61%
-2.84M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
GSK plc
9.19M
16.31%
--
--
Mar 27, 2025
Pfizer Inc
2.36M
4.19%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.99M
3.53%
+39.47K
+2.02%
Sep 30, 2025
Anson Funds Management LP.
1.60M
2.85%
-11.90K
-0.74%
Sep 30, 2025
Renaissance Technologies LLC
1.45M
2.58%
+620.60K
+74.58%
Sep 30, 2025
Alphabet, Inc.
889.98K
1.58%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
527.48K
0.94%
+16.78K
+3.29%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
433.55K
0.77%
--
--
Sep 30, 2025
Rajavelu (Esther)
188.41K
0.33%
-40.27K
-17.61%
Nov 07, 2025
Mahadevia (Ankit)
364.22K
0.65%
-6.57K
-1.77%
Aug 28, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.63%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
占比0.63%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
